PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share





William G. Wierda, MD, PhD - New Standards for CLL Care With BTK Inhibitors: Using Evidence to Make Personalized Treatment Choices


Go online to PeerView.com/SYN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView Seminar and Tumor Board activity, CLL experts discuss how BTK inhibitors are changing the treatment landscape for patients with CLL. Find out how these experts make treatment choices for upfront and relapsed disease, factoring safety into the decision to use BTK inhibitors and sequencing strategies. These clinical conversations are supported by scientific seminars designed to reinforce the lessons of recent, relevant evidence and by discussions on the integration of BTK inhibitors in a range of CLL patient populations and treatment settings. Upon completion of this accredited CE activity, participants should be better able to: Cite the selectivity and safety profiles of first- and second-generation BTK inhibitors available for use in CLL, Discuss safety and efficacy evidence related to the use of BTK inhibitors as single-agent or combination regimens in treatment-naive and relapsed CLL, and in the setting of BTK inhibitor intolerance, Select single-agent, sequential, or combination strategies using BTK inhibitors in treatment-naïve or relapsed CLL based on prognostic features, safety profiles, and therapeutic history, Manage the unique spectrum of adverse events associated with the use of BTK inhibitors in patients with CLL.


share







 2021-07-16  1h36m